EP2398529A1 - Simulation of patient drain phase in peritoneal dialysis - Google Patents

Simulation of patient drain phase in peritoneal dialysis

Info

Publication number
EP2398529A1
EP2398529A1 EP10705073A EP10705073A EP2398529A1 EP 2398529 A1 EP2398529 A1 EP 2398529A1 EP 10705073 A EP10705073 A EP 10705073A EP 10705073 A EP10705073 A EP 10705073A EP 2398529 A1 EP2398529 A1 EP 2398529A1
Authority
EP
European Patent Office
Prior art keywords
drain
patient
segment
time
volume
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP10705073A
Other languages
German (de)
French (fr)
Other versions
EP2398529B1 (en
Inventor
Alp Akonur
Ying-Cheng Lo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baxter Healthcare SA
Baxter International Inc
Original Assignee
Baxter Healthcare SA
Baxter International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Healthcare SA, Baxter International Inc filed Critical Baxter Healthcare SA
Publication of EP2398529A1 publication Critical patent/EP2398529A1/en
Application granted granted Critical
Publication of EP2398529B1 publication Critical patent/EP2398529B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
    • A61M1/28—Peritoneal dialysis ; Other peritoneal treatment, e.g. oxygenation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
    • A61M1/28—Peritoneal dialysis ; Other peritoneal treatment, e.g. oxygenation
    • A61M1/282—Operational modes
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/50—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders

Definitions

  • the present disclosure relates to medical fluid delivery and in particular to peritoneal dialysis fluid delivery.
  • Kidney failure and reduced kidney function have been treated with dialysis. Dialysis removes waste, toxins and excess water from the body that would otherwise have been removed by normal functioning kidneys. Dialysis treatment for replacement of kidney functions is critical to many people because the treatment is life saving. One who has failed kidneys could not continue to live without replacing at least the filtration functions of the kidneys.
  • peritoneal dialysis uses a dialysis solution or "dialysate", which is infused into a patient's peritoneal cavity through a catheter implanted in the cavity.
  • the dialysate contacts the patient's peritoneal membrane in the peritoneal cavity.
  • Waste, toxins and excess water pass from the patient's bloodstream through the peritoneal membrane and into the dialysate.
  • the transfer of waste, toxins, and water from the bloodstream into the dialysate occurs due to diffusion and osmosis, i.e., an osmotic gradient occurs across the membrane.
  • the spent dialysate drains from the patient's peritoneal cavity and removes the waste, toxins and excess water from the patient. This cycle is repeated.
  • CAPD continuous ambulatory peritoneal dialysis
  • APD automated peritoneal dialysis
  • CAPD is a manual dialysis treatment, in which the patient connects an implanted catheter to a drain and allows a spent dialysate fluid to drain from the patient's peritoneal cavity. The patient then connects the catheter to a bag of fresh dialysate and manually infuses fresh dialysate through the catheter and into the patient's peritoneal cavity. The patient disconnects the catheter from the fresh dialysate bag and allows the dialysate to dwell within the cavity to transfer waste, toxins and excess water from the patient's bloodstream to the dialysate solution. After a dwell period, the patient repeats the manual dialysis procedure.
  • APD In CAPD the patient performs several drain, fill, and dwell cycles during the day, for example, about four times per day. Each treatment cycle typically takes about four to five hours.
  • APD is similar to CAPD in that the dialysis treatment includes a drain, fill, and dwell cycle.
  • APD machines perform four to five cycles of peritoneal dialysis treatment automatically, typically overnight while the patient sleeps.
  • APD machines connect fluidly to an implanted catheter, to one or more sources or bags of fresh dialysate and to a fluid drain.
  • the APD machines pump fresh dialysate from the dialysate source, through the catheter, into the patient's peritoneal cavity and allow the dialysate to dwell within the cavity so that the transfer of waste, toxins and excess water from the patient's bloodstream to the dialysate solution can take place.
  • the APD machines then pump spent dialysate from the peritoneal cavity, though the catheter, to the drain.
  • APD machines are typically computer controlled so that the dialysis treatment occurs automatically when the patient is connected to the dialysis machine, for example, when the patient sleeps. That is, the APD systems automatically and sequentially pump fluid into the peritoneal cavity, allow for a dwell, pump fluid out of the peritoneal cavity and repeat the procedure. As with the manual process, several drain, fill, and dwell cycles will occur during APD.
  • a "last fill” is typically used at the end of APD, which remains in the peritoneal cavity of the patient when the patient disconnects from the dialysis machine for the day.
  • the therapy must allow for a certain amount of time for the patient drain phase. It is important that the drain phase be sufficiently long to allow the patient to drain as completely as possible. On the other hand, if too much time is allowed for the drain phase, that is, the patient is basically finished draining too far in advance of the end of the drain phase, then the drain phase is extending needlessly into time that the patient could be filling or is appending the last fill's dwell phase needlessly.
  • the present disclosure sets forth a method and apparatus for predicting a patient's optimal drain phase time.
  • the optimal drain phase time is useful for at least two purposes.
  • the optimal drain phase time can be implemented into the patient's continuous ambulatory peritoneal dialysis ("CAPD") or automated peritoneal dialysis (“APD”) treatment.
  • the optimal drain phase time can be used in the further modeling of possible treatments or therapy regimes for the patient, one or more desirable ones of which can then be selected for actual use.
  • the further treatment or prescription modeling can be done using a three-pore model as discussed below.
  • the drain phase modeling attempts to match the patient's actual drain profile given certain inputs.
  • One important patient specific input is maximum drain flowrate or Qmax- Qmax typically occurs at the start of the drain. Some patients will drain more quickly than others due to patient-specific physical characteristics. Also, the position of the patient affects Qmax- A patient standing or sitting may drain quicker than if the same patient is lying down in a supine or prone position.
  • Q max is determined in one embodiment by experimentation with the patient in a drain position that the patient expects to be for at least most treatments.
  • Figs. 1 and 2 typical drain volume and corresponding flowrate profiles, respectively, are shown. The profiles were derived in a study by Brandes J. C, Packard, J. W., Watters S. K., Fritsche C, Optimization of Dialysate Flow and Mass Transfer During Automated Peritoneal Dialysis, American Journal of Kidney Diseases, Vol. 25, No. 4 (April), 1995, pp. 603-610.
  • Fig. 1 shows a constant drop in drain volume from a full volume of about 2000 ml to a transition drain volume of about 350 to 400 ml.
  • an equation has been formed that models the first and second segments.
  • the equation relies principally on Q max for the first segment.
  • the equation employs a switching component ⁇ that either (i) switches the first segment portion of the equation on and the second segment portion of the equation off or (ii) switches the first segment portion of the equation off and the second segment portion of the equation on.
  • the transition time (or volume) at which switching component ⁇ switches from 1 to 0 is determined empirically, e.g., the duration of the constant high flow Qmax can be measured for each individual patient, and for a particular drain position.
  • the second segment portion of the equation also employs an exponential drain rate constant ⁇ , which is patient specific and is determined empirically. The equation relies principally on ⁇ for the second segment.
  • the drain modeling equation can be used in a number of ways. First, it can be used to form individual settings for flowrate threshold (“FRT”) and/or minimum drain volume (“MDV”). One or both of FRT and MDV may be set as alarm limits in an automated peritoneal dialysis (“APD”) machine (which can use either gravity draining or pumped draining).
  • FRT flowrate threshold
  • MDV minimum drain volume
  • APD automated peritoneal dialysis
  • the drain modeling equation can be used to more accurately model a patient's reaction to therapy, e.g., via a three-pore model.
  • the three-pore model uses a drain time (or dwell time, which is a function of drain time) in one or more places to model a particular patient's reaction to a particular therapy prescription.
  • the drain modeling equation can be used to set drain and dwell times or periods for actual operation of an APD machine, for example, performing a multiple exchange therapy.
  • the machine can be a gravity drain machine or drain via a pump.
  • the drain modeling equation can be used to set drain times or periods for patients performing manual peritoneal dialysis or CAPD.
  • Figs. 1 and 2 are drain volume and drain phase flowrate profiles derived from actual patient data via a study.
  • Figs. 3 and 4 are drain volume and drain phase flowrate profiles derived via the modeling method and apparatus of the present disclosure.
  • Fig. 5 is a schematic diagram illustrating how the drain volume modeling method and apparatus of the present disclosure is used with kinetic modeling of patient therapy outcomes, e.g., using a three-pore model.
  • Figs. 6A to 6C illustrate a first therapy modeled via kinetic model using information obtained from the drain volume modeling method and apparatus of the present disclosure.
  • Fig. 7 is a graph illustrating peritoneal volume over time for the therapy illustrated in Figs. 6 A to 6C.
  • Figs. 8A to 8C illustrate a second therapy modeled via kinetic model using information obtained from the drain volume modeling method and apparatus of the present disclosure.
  • Fig. 9 is a graph illustrating peritoneal volume over time for the therapy illustrated in Figs. 8 A to 8C.
  • drain volume modeling method and apparatus of the present disclosure uses the concepts and terminology described below.
  • Maximum drain flowrate, Q ma ⁇ is the initial drain flowrate, which should be a maximum flowrate of the drain flowrate profile.
  • the present disclosure applies to different kinds of APD machines.
  • the APD machine can use a gravity fill and drain, in which the supply bag is placed elevationally above the patient and the drain bag is placed elevationally below the patient.
  • Q max is determined empirically as discussed below.
  • Q max is also determined empirically for continuous ambulatory peritoneal dialysis ("CAPD”), which also uses gravity for filling and draining.
  • the HomeChoice® machine made by the assignee of the present disclosure, pumps spent fluid from the patient to drain.
  • Q max is set by the pump speed, does not need to be determined empirically, and is independent of the patient's drain position.
  • Q max is assumed to remain constant until the patient drain transitions to an exponential decay portion or segment of the profile.
  • Q max is patient specific and is also patient drain position specific.
  • Q max is determined empirically by, for example, weighing the patient's drain over time for a number of exchanges and then averaging the resulting rate.
  • Q max may vary for a patient depending upon whether the patient is sitting, laying down or standing during drain. It is contemplated therefore to obtain empirical data for Q max while the patient is positioned for drain in a position that the patient intends to be for most or all drains.
  • an automated peritoneal dialysis (“APD”) machine can be programmed to ask the patient which drain position the patient intends to use for the current treatment.
  • Flow transition percent is the percentage of the peritoneal volume at which the patient drain transitions from the first segment, having constant drain flowrate Q max , to the second segment having the decaying exponential flowrate.
  • FTP sets the volume (or percentage of total time) at which switching component ⁇ , discussed in detail herein, switches from 1 to 0.
  • FTP is patient specific and is determined empirically regardless of the type of APD machine (gravity drain or pump to drain) used. FTP may also be dependent upon patient drain position for gravity fed systems or treatments.
  • the second drain profile segment having the decaying exponential flowrate, is controlled in large part by a decaying exponential constant ⁇ , which is also patient specific and is determined empirically regardless of the type of APD machine (gravity drain or pump to drain) used or if CAPD is performed instead, ⁇ itself may depend on drain type, pump or gravity, and perhaps pump type, e.g., peristaltic versus membrane, ⁇ may also be dependent upon patient drain position for gravity fed systems or treatments, ⁇ is determined by obtaining multiple data points (volume for a given time and flowrate for a given time) during the second or decaying exponential drain flow and volume segment.
  • ⁇ is also patient specific and is determined empirically regardless of the type of APD machine (gravity drain or pump to drain) used or if CAPD is performed instead, ⁇ itself may depend on drain type, pump or gravity, and perhaps pump type, e.g., peristaltic versus membrane, ⁇ may also be dependent upon patient drain position for gravity fed systems or treatments, ⁇ is determined by obtaining multiple data points (volume
  • ⁇ can for example be in a range of 0.1 to 0.15.
  • MDP minimum drain percentage
  • MDP sets a drain limit above which the patient's drain volume must reach during the drain phase. If, for example, the patient does not drain at least eighty percent of the total spent volume in the patient's peritoneum, The APD will sound an alarm and therapy may be halted, preventing the machine from advancing to the next fill phase until the low drain is addressed.
  • MDP can be used with the modeled drain profiles to determine an appropriate dwell time for the patient, in particular, it sets a minimum dwell time to reach MDP
  • Flowrate threshold may also be set in the software of an APD machine for alarm purposes.
  • FRT sets a minimum drain flowrate level below which the machine may alarm, for example, indicating that the drain flowrate is so low that the treatment in essence is wasting time by continuing drain.
  • FRT can alternatively be set to define a drain flow limit below which the drain is stopped.
  • FTP and MDP can be used, alone or in combination, with the modeled drain profiles to determine an appropriate dwell time for the patient, which ensures that the dwell time is long enough for MDP to be met but does not continue long enough for the drain flowrate to fall below FTP.
  • drain volume and drain flowrate profiles are shown, respectively, which have been modeled to attempt to match the actual drain volume and drain flowrate profiles of Figs. 1 and 2.
  • the drain volume profile of Fig. 3 is obtained via the following equation or algorithm:
  • V D [VDO - Q ma ⁇ *t]* ⁇ + [VDO *e " ⁇ t ]*(l - ⁇ ), wherein
  • V D is an instantaneous remaining drain volume in the patient at time t
  • V DO is an initial patient drain volume (fill volume plus UF accumulated over previous dwell);
  • ⁇ discussed above is a switching component (from 1 to 0 at FTP), which is based on time or volume; ⁇ discussed above is a decaying exponential constant; and t is time.
  • the modeled flowrate profile of Fig. 4 is determined by dividing a change in volume by a corresponding change in time, e.g., drop from 2300 ml to 2600 ml over first two minutes leading to flowrate over that period of 350 ml/min.
  • Specific flowrate values can be obtained via a derivative dV/dT, especially in the second, non-linear, segment.
  • V DO is the previous fill volume plus an amount of ultrafiltrate ("UF") removed from the patient over the last dwell.
  • the amount of UF can be estimated via a three-pore model given certain parameters, such as patient physiological characteristics (ability to remove UF), dextrose level of dialysate used and dwell time. For example, if the patient fill is 2000 ml of fresh dialysate and it is determined from a patient kinetic model, such as a three-pore model, or perhaps experimentally, that the patient will acquire 300 ml of ultrafiltrate over the course of a known dwell period, V DO will be set to 2300 ml.
  • Q max is determined empirically or set via pump speed.
  • a schematic showing fill, dwell and drain phases of a peritoneal dialysis treatment illustrates how the drain volume modeling method and apparatus of the present disclosure interfaces with the kinetic modeling of patient therapy outcomes, e.g., using a three-pore model.
  • the duration of the fill phase in APD is set via a pump speed.
  • the duration of the fill phase in CAPD is determined principally by head height of the fill bag above the patient.
  • Dwell phase duration and drain phase duration are related.
  • a treatment typically requires multiple, e.g., four, fills that are made over an entire treatment, e.g., eight hours.
  • the set fill times leave only so much time for the dwell and drain phases. The less time needed for drain, the more time left for dwell, which is desirable from both clearance and UF standpoints.
  • FIGs. 6A to 6C one example therapy modeled using a three- pore kinetic model is illustrated.
  • the three-pore kinetic model used drain times selected from drain volume and drain flowrate profiles, similar to Figs. 3 and 4, which were determined via the equation above.
  • the patient undergoes four exchanges of two liter fills each, totaling eight liters.
  • PET characteristic is H or high meaning the patient in general has high toxin and glucose clearances.
  • FIG. 6B A modeled drain time and corresponding drain volume is shown for each cycle in Fig. 6B.
  • the drain volume met the MDP requirement of 85%
  • the minimum drain flowrate met the FRT requirement of 75 ml/min, both of which are shown in Fig. 6A.
  • Fig. 6A also shows patient specific parameters, namely, an FTP of 75% (percentage of drain after which switching component ⁇ changes from 1 to 0) and a Q max of 80 ml/min.
  • the drain time and drain volume selected vary from cycle to cycle because initial drain volume V DO varies from cycle to cycle.
  • Initial drain volume V DO varies from cycle to cycle because residual volume (volume remaining in the patient's peritoneum after drain is completed) varies from cycle to cycle.
  • residual volume jumps from 150 ml after cycle 1 to 537 ml for cycle 2 and then increases more slowly to 631 ml and 654 ml for cycles three and four.
  • Fig. 6C shows the three-pore kinetic model's predicted UF removed for the therapy of Fig. 6B.
  • Fig. 6B and Fig. 7 (graphing peak volume over the cycles) highlight one concern about the "four exchange each of a two liter fill" therapy of Fig. 6B, namely, that the predicted peak volume of the patient indicates the patient may become overfilled.
  • a peak volume of roughly 2700 ml may be too high for many patients.
  • Figs. 8A to 8C a second example therapy modeled using a three-pore kinetic model is illustrated.
  • the three-pore kinetic model again used drain times selected from drain volume and drain flowrate profiles, similar to Figs. 3 and 4, calculated via the equation above.
  • the patient instead of four exchanges of two liter fills each, the patient undergoes a first exchange using a two liter fill, and then four exchanges each of a 1.5 liter fill, totaling eight liters like above. PET characteristic is again high.
  • FIG. 8B A modeled drain time and corresponding drain volume is shown for each cycle in Fig. 8B.
  • the drain volume met the MDP requirement of 85% and the minimum drain flowrate met the FRT requirement of 75 ml/min shown in Fig. 8A.
  • Fig. 8A also shows patient specific parameters of an FTP of 65% and a Q max of 80 ml/min.
  • the drain time and drain volume vary from cycle to cycle because initial drain volume V DO varies from cycle to cycle.
  • the first drain volume is the biggest and the first drain time is the longest because the first fill is the biggest, namely, two liters versus 1.5 liters for the remaining four fills.
  • the drain volumes and drain times increase from cycle two to cycle five because residual volume increases in each instance from cycle two to cycle five.
  • Figs. 8B and 9 highlight that five exchange or cycle therapy of Fig. 8B predicts a reduction of the maximum peak volume to roughly 2350 ml, which may be better suited for the particular patient.
  • Fig. 8C shows the three-pore kinetic model's predicted UF removed for the therapy of Fig. 8B. The UF removed and overall clearances are comparable to those of Fig. 6C, and the patient absorbs less glucose, which is beneficial because the patient does not gain as much weight. Thus, assuming that the additional exchange can be done in a prescribed or desired total therapy duration, the therapy of Fig. 8B may be more desirable than the therapy of Fig. 6B. In any case, the more accurately predicted drain times and volumes discussed herein allow the therapies of Figs. 6B and 8B to be predicted more accurately, so that a better and more informed decision can be made for the patient.

Landscapes

  • Health & Medical Sciences (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Veterinary Medicine (AREA)
  • Medical Informatics (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Primary Health Care (AREA)
  • External Artificial Organs (AREA)

Abstract

A method of modeling a patient's peritoneal dialysis drain phase includes (i) modeling a first segment of a drain phase curve as having a constant flowrate; (ii) modeling a second segment of a drain phase curve as having a decaying exponential flowrate; and (iii) incorporating a switching component into the first and second components so that (a) at a first time the first segment is active and while the second segment is inactive and (b) at a second time the first segment is inactive and while the second segment is active.

Description

TITLE SIMULATION OF PATIENT DRAIN PHASE IN PERITONEAL DIALYSIS
BACKGROUND
[0001] The present disclosure relates to medical fluid delivery and in particular to peritoneal dialysis fluid delivery.
[0002] Due to disease or other causes, a person's renal system can fail. In renal failure of any cause, there are several physiological derangements. The balance of water, minerals and the excretion of daily metabolic load is no longer possible in renal failure. During renal failure, toxic end products of nitrogen metabolism (urea, creatinine, uric acid, and others) can accumulate in blood and tissues.
[0003] Kidney failure and reduced kidney function have been treated with dialysis. Dialysis removes waste, toxins and excess water from the body that would otherwise have been removed by normal functioning kidneys. Dialysis treatment for replacement of kidney functions is critical to many people because the treatment is life saving. One who has failed kidneys could not continue to live without replacing at least the filtration functions of the kidneys.
[0004] One type of dialysis is peritoneal dialysis. Peritoneal dialysis uses a dialysis solution or "dialysate", which is infused into a patient's peritoneal cavity through a catheter implanted in the cavity. The dialysate contacts the patient's peritoneal membrane in the peritoneal cavity. Waste, toxins and excess water pass from the patient's bloodstream through the peritoneal membrane and into the dialysate. The transfer of waste, toxins, and water from the bloodstream into the dialysate occurs due to diffusion and osmosis, i.e., an osmotic gradient occurs across the membrane. The spent dialysate drains from the patient's peritoneal cavity and removes the waste, toxins and excess water from the patient. This cycle is repeated.
[0005] There are various types of peritoneal dialysis therapies, including continuous ambulatory peritoneal dialysis ("CAPD") and automated peritoneal dialysis ("APD"). CAPD is a manual dialysis treatment, in which the patient connects an implanted catheter to a drain and allows a spent dialysate fluid to drain from the patient's peritoneal cavity. The patient then connects the catheter to a bag of fresh dialysate and manually infuses fresh dialysate through the catheter and into the patient's peritoneal cavity. The patient disconnects the catheter from the fresh dialysate bag and allows the dialysate to dwell within the cavity to transfer waste, toxins and excess water from the patient's bloodstream to the dialysate solution. After a dwell period, the patient repeats the manual dialysis procedure.
[0006] In CAPD the patient performs several drain, fill, and dwell cycles during the day, for example, about four times per day. Each treatment cycle typically takes about four to five hours. APD is similar to CAPD in that the dialysis treatment includes a drain, fill, and dwell cycle. APD machines, however, perform four to five cycles of peritoneal dialysis treatment automatically, typically overnight while the patient sleeps. Like CAPD, APD machines connect fluidly to an implanted catheter, to one or more sources or bags of fresh dialysate and to a fluid drain.
[0007] The APD machines pump fresh dialysate from the dialysate source, through the catheter, into the patient's peritoneal cavity and allow the dialysate to dwell within the cavity so that the transfer of waste, toxins and excess water from the patient's bloodstream to the dialysate solution can take place. The APD machines then pump spent dialysate from the peritoneal cavity, though the catheter, to the drain. APD machines are typically computer controlled so that the dialysis treatment occurs automatically when the patient is connected to the dialysis machine, for example, when the patient sleeps. That is, the APD systems automatically and sequentially pump fluid into the peritoneal cavity, allow for a dwell, pump fluid out of the peritoneal cavity and repeat the procedure. As with the manual process, several drain, fill, and dwell cycles will occur during APD. A "last fill" is typically used at the end of APD, which remains in the peritoneal cavity of the patient when the patient disconnects from the dialysis machine for the day.
[0008] In both CAPD and APD, the therapy must allow for a certain amount of time for the patient drain phase. It is important that the drain phase be sufficiently long to allow the patient to drain as completely as possible. On the other hand, if too much time is allowed for the drain phase, that is, the patient is basically finished draining too far in advance of the end of the drain phase, then the drain phase is extending needlessly into time that the patient could be filling or is appending the last fill's dwell phase needlessly. A need accordingly exists for a way to predict and optimize drain phase time to allow for the patient to drain completely or as much as is reasonably possible without needlessly extending drain time and wasting time that could be used to increase therapy dwell.
SUMMARY
[0009] The present disclosure sets forth a method and apparatus for predicting a patient's optimal drain phase time. The optimal drain phase time is useful for at least two purposes. First, the optimal drain phase time can be implemented into the patient's continuous ambulatory peritoneal dialysis ("CAPD") or automated peritoneal dialysis ("APD") treatment. Second, the optimal drain phase time can be used in the further modeling of possible treatments or therapy regimes for the patient, one or more desirable ones of which can then be selected for actual use. The further treatment or prescription modeling can be done using a three-pore model as discussed below.
[0010] The drain phase modeling attempts to match the patient's actual drain profile given certain inputs. One important patient specific input is maximum drain flowrate or Qmax- Qmax typically occurs at the start of the drain. Some patients will drain more quickly than others due to patient-specific physical characteristics. Also, the position of the patient affects Qmax- A patient standing or sitting may drain quicker than if the same patient is lying down in a supine or prone position. Qmax is determined in one embodiment by experimentation with the patient in a drain position that the patient expects to be for at least most treatments.
[0011] Referring now to the drawings and in particular to Figs. 1 and 2, typical drain volume and corresponding flowrate profiles, respectively, are shown. The profiles were derived in a study by Brandes J. C, Packard, J. W., Watters S. K., Fritsche C, Optimization of Dialysate Flow and Mass Transfer During Automated Peritoneal Dialysis, American Journal of Kidney Diseases, Vol. 25, No. 4 (April), 1995, pp. 603-610. Fig. 1 shows a constant drop in drain volume from a full volume of about 2000 ml to a transition drain volume of about 350 to 400 ml. This constant drop occurs while flowrate is generally at a maximum, e.g., Qmaχ, which is about 350 ml/min as seen in Fig. 2. Below the transition volume, the volume drains according to a decaying exponential curve. Drain flowrate after the transition point also slows to zero according to a similar curve. The transition point in both Figs. 1 and 2 separates a first segment from a second segment as discussed in detail below.
[0012] According to the present method and apparatus, an equation has been formed that models the first and second segments. The equation relies principally on Qmax for the first segment. The equation employs a switching component Φ that either (i) switches the first segment portion of the equation on and the second segment portion of the equation off or (ii) switches the first segment portion of the equation off and the second segment portion of the equation on. The transition time (or volume) at which switching component Φ switches from 1 to 0 is determined empirically, e.g., the duration of the constant high flow Qmax can be measured for each individual patient, and for a particular drain position. The second segment portion of the equation also employs an exponential drain rate constant α, which is patient specific and is determined empirically. The equation relies principally on α for the second segment.
[0013] The drain modeling equation can be used in a number of ways. First, it can be used to form individual settings for flowrate threshold ("FRT") and/or minimum drain volume ("MDV"). One or both of FRT and MDV may be set as alarm limits in an automated peritoneal dialysis ("APD") machine (which can use either gravity draining or pumped draining).
[0014] Second, the drain modeling equation can be used to more accurately model a patient's reaction to therapy, e.g., via a three-pore model. For example, the three-pore model uses a drain time (or dwell time, which is a function of drain time) in one or more places to model a particular patient's reaction to a particular therapy prescription.
[0015] Third, the drain modeling equation can be used to set drain and dwell times or periods for actual operation of an APD machine, for example, performing a multiple exchange therapy. Again, the machine can be a gravity drain machine or drain via a pump.
[0016] Fourth, the drain modeling equation can be used to set drain times or periods for patients performing manual peritoneal dialysis or CAPD.
[0017] It is accordingly an advantage of the present disclosure to provide a method and apparatus that attempt to optimize a drain phase in peritoneal dialysis.
[0018] It is another advantage of the present disclosure to provide a method and apparatus that attempt to minimize drain time.
[0019] It is a further advantage of the present disclosure to provide a method and apparatus that attempt to maximize drain volume.
[0020] It is yet another advantage of the present disclosure to provide a method and apparatus that attempt to prevent patient overfill.
[0021] It is yet a further advantage of the present disclosure to provide a method and apparatus that attempt to prevent low drain flowrate alarms.
[0022] It is still another advantage of the present disclosure to provide a method and apparatus that attempt to improve estimation of therapy outcome parameters such as UF, urea clearance and creatinine clearance.
[0023] Additional features and advantages are described herein, and will be apparent from the following Detailed Description and the figures. BRIEF DESCRIPTION OF THE FIGURES
[0024] Figs. 1 and 2 are drain volume and drain phase flowrate profiles derived from actual patient data via a study.
[0025] Figs. 3 and 4 are drain volume and drain phase flowrate profiles derived via the modeling method and apparatus of the present disclosure.
[0026] Fig. 5 is a schematic diagram illustrating how the drain volume modeling method and apparatus of the present disclosure is used with kinetic modeling of patient therapy outcomes, e.g., using a three-pore model.
[0027] Figs. 6A to 6C illustrate a first therapy modeled via kinetic model using information obtained from the drain volume modeling method and apparatus of the present disclosure.
[0028] Fig. 7 is a graph illustrating peritoneal volume over time for the therapy illustrated in Figs. 6 A to 6C.
[0029] Figs. 8A to 8C illustrate a second therapy modeled via kinetic model using information obtained from the drain volume modeling method and apparatus of the present disclosure.
[0030] Fig. 9 is a graph illustrating peritoneal volume over time for the therapy illustrated in Figs. 8 A to 8C.
DETAILED DESCRIPTION
[0031] The drain volume modeling method and apparatus of the present disclosure uses the concepts and terminology described below.
[0032] Maximum drain flowrate, Qmaχ, is the initial drain flowrate, which should be a maximum flowrate of the drain flowrate profile. The present disclosure applies to different kinds of APD machines. For example, the APD machine can use a gravity fill and drain, in which the supply bag is placed elevationally above the patient and the drain bag is placed elevationally below the patient. For such a machine, Qmax is determined empirically as discussed below. Qmax is also determined empirically for continuous ambulatory peritoneal dialysis ("CAPD"), which also uses gravity for filling and draining. The HomeChoice® machine, made by the assignee of the present disclosure, pumps spent fluid from the patient to drain. Here, Qmax is set by the pump speed, does not need to be determined empirically, and is independent of the patient's drain position. [0033] For modeling purposes, Qmax is assumed to remain constant until the patient drain transitions to an exponential decay portion or segment of the profile. Qmax is patient specific and is also patient drain position specific. Qmax is determined empirically by, for example, weighing the patient's drain over time for a number of exchanges and then averaging the resulting rate. Qmax may vary for a patient depending upon whether the patient is sitting, laying down or standing during drain. It is contemplated therefore to obtain empirical data for Qmax while the patient is positioned for drain in a position that the patient intends to be for most or all drains. It is also contemplated to obtain empirical data for Qmax while the patient is in different positions for drain, e.g., one set of data while the patient is standing for drain, one set of data while the patient is sitting for drain, and a third set of data while the patient is laying down for drain. In such case, an automated peritoneal dialysis ("APD") machine can be programmed to ask the patient which drain position the patient intends to use for the current treatment.
[0034] Flow transition percent ("FTP") is the percentage of the peritoneal volume at which the patient drain transitions from the first segment, having constant drain flowrate Qmax, to the second segment having the decaying exponential flowrate. FTP sets the volume (or percentage of total time) at which switching component Φ, discussed in detail herein, switches from 1 to 0. FTP is patient specific and is determined empirically regardless of the type of APD machine (gravity drain or pump to drain) used. FTP may also be dependent upon patient drain position for gravity fed systems or treatments.
[0035] The second drain profile segment, having the decaying exponential flowrate, is controlled in large part by a decaying exponential constant α, which is also patient specific and is determined empirically regardless of the type of APD machine (gravity drain or pump to drain) used or if CAPD is performed instead, α itself may depend on drain type, pump or gravity, and perhaps pump type, e.g., peristaltic versus membrane, α may also be dependent upon patient drain position for gravity fed systems or treatments, α is determined by obtaining multiple data points (volume for a given time and flowrate for a given time) during the second or decaying exponential drain flow and volume segment. Different "potential" values of α are then plugged into the second segment of the drain model shown below until a value of α that outputs correct volume and correct flowrate values for the corresponding points in time, or which best match the measured data, is obtained, α can for example be in a range of 0.1 to 0.15.
[0036] One parameter that may be set in the software of an APD machine for alarm purposes is a minimum drain percentage ("MDP"). MDP sets a drain limit above which the patient's drain volume must reach during the drain phase. If, for example, the patient does not drain at least eighty percent of the total spent volume in the patient's peritoneum, The APD will sound an alarm and therapy may be halted, preventing the machine from advancing to the next fill phase until the low drain is addressed. As discussed below, MDP can be used with the modeled drain profiles to determine an appropriate dwell time for the patient, in particular, it sets a minimum dwell time to reach MDP
[0037] Flowrate threshold ("FRT") may also be set in the software of an APD machine for alarm purposes. FRT sets a minimum drain flowrate level below which the machine may alarm, for example, indicating that the drain flowrate is so low that the treatment in essence is wasting time by continuing drain. FRT can alternatively be set to define a drain flow limit below which the drain is stopped. As discussed below, FTP and MDP can be used, alone or in combination, with the modeled drain profiles to determine an appropriate dwell time for the patient, which ensures that the dwell time is long enough for MDP to be met but does not continue long enough for the drain flowrate to fall below FTP.
[0038] Referring now to Figs. 3 and 4, drain volume and drain flowrate profiles are shown, respectively, which have been modeled to attempt to match the actual drain volume and drain flowrate profiles of Figs. 1 and 2. The drain volume profile of Fig. 3 is obtained via the following equation or algorithm:
VD= [VDO - Qmaχ*t]*Φ + [VDO *e"αt]*(l - Φ), wherein
VD is an instantaneous remaining drain volume in the patient at time t
VDO is an initial patient drain volume (fill volume plus UF accumulated over previous dwell);
Qmax discussed above is a starting flowrate and is assumed to be constant;
Φ discussed above is a switching component (from 1 to 0 at FTP), which is based on time or volume; α discussed above is a decaying exponential constant; and t is time.
[0039] The modeled flowrate profile of Fig. 4 is determined by dividing a change in volume by a corresponding change in time, e.g., drop from 2300 ml to 2600 ml over first two minutes leading to flowrate over that period of 350 ml/min. Specific flowrate values can be obtained via a derivative dV/dT, especially in the second, non-linear, segment.
[0040] The equation above and resulting profiles of Figs. 3 and 4 show a first segment that is dependent on VDO and Qmax. VDO is the previous fill volume plus an amount of ultrafiltrate ("UF") removed from the patient over the last dwell. The amount of UF can be estimated via a three-pore model given certain parameters, such as patient physiological characteristics (ability to remove UF), dextrose level of dialysate used and dwell time. For example, if the patient fill is 2000 ml of fresh dialysate and it is determined from a patient kinetic model, such as a three-pore model, or perhaps experimentally, that the patient will acquire 300 ml of ultrafiltrate over the course of a known dwell period, VDO will be set to 2300 ml. Qmax is determined empirically or set via pump speed.
[0041] The equation above and resulting profiles of Figs. 3 and 4 show a second segment that is dependent on VDO and α. α is determined empirically as discussed above. The transition point in the above equation occurs when Φ switches from 1 to 0, which is determined empirically. The corresponding transition point in the profiles of Figs. 3 and 4 occurs when the straight line transitions to the curved or exponentially decaying line.
[0042] Referring now to Fig. 5, a schematic showing fill, dwell and drain phases of a peritoneal dialysis treatment illustrates how the drain volume modeling method and apparatus of the present disclosure interfaces with the kinetic modeling of patient therapy outcomes, e.g., using a three-pore model. The duration of the fill phase in APD is set via a pump speed. The duration of the fill phase in CAPD is determined principally by head height of the fill bag above the patient.
[0043] Dwell phase duration and drain phase duration are related. A treatment typically requires multiple, e.g., four, fills that are made over an entire treatment, e.g., eight hours. The set fill times leave only so much time for the dwell and drain phases. The less time needed for drain, the more time left for dwell, which is desirable from both clearance and UF standpoints.
[0044] Further, accurately modeling an adequate (MDP satisfied) but efficient (FTP satisfied) allows the dwell phase times to be determined accurately given the set fill times. The dwell phase times are important to the kinetic modeling as seen in Fig. 5. Thus, determining accurate dwell times allows the kinetic modeling of patient results to different therapy prescriptions to be done more accurately. One suitable modified three-pore kinetic model is described in Rippe B., Sterlin G., and Haraldsson B., Computer Simulations of Peritoneal Fluid Transport in CAPD. Kidney Int. 1991; 40: 315 to 325. Another suitable modified three-pore kinetic model is described in Vonesh E. F. and Rippe B., Net Fluid Adsorption Under Membrane Transport Models of Peritoneal Dialysis, Blood Purif. 1992; 10: 209 to 226, the entire contents of each of which are incorporated herein by reference and relied upon. [0045] Referring now to Figs. 6A to 6C, one example therapy modeled using a three- pore kinetic model is illustrated. The three-pore kinetic model used drain times selected from drain volume and drain flowrate profiles, similar to Figs. 3 and 4, which were determined via the equation above. Here, the patient undergoes four exchanges of two liter fills each, totaling eight liters. PET characteristic is H or high meaning the patient in general has high toxin and glucose clearances.
[0046] A modeled drain time and corresponding drain volume is shown for each cycle in Fig. 6B. In each case, the drain volume met the MDP requirement of 85%, and the minimum drain flowrate met the FRT requirement of 75 ml/min, both of which are shown in Fig. 6A. Fig. 6A also shows patient specific parameters, namely, an FTP of 75% (percentage of drain after which switching component Φ changes from 1 to 0) and a Qmax of 80 ml/min.
[0047] As seen in Fig. 6B, the drain time and drain volume selected vary from cycle to cycle because initial drain volume VDO varies from cycle to cycle. Initial drain volume VDO varies from cycle to cycle because residual volume (volume remaining in the patient's peritoneum after drain is completed) varies from cycle to cycle. As seen in Fig. 6B, residual volume jumps from 150 ml after cycle 1 to 537 ml for cycle 2 and then increases more slowly to 631 ml and 654 ml for cycles three and four.
[0048] Fig. 6C shows the three-pore kinetic model's predicted UF removed for the therapy of Fig. 6B. Fig. 6B and Fig. 7 (graphing peak volume over the cycles) highlight one concern about the "four exchange each of a two liter fill" therapy of Fig. 6B, namely, that the predicted peak volume of the patient indicates the patient may become overfilled. A peak volume of roughly 2700 ml may be too high for many patients.
[0049] Referring now to Figs. 8A to 8C, a second example therapy modeled using a three-pore kinetic model is illustrated. The three-pore kinetic model again used drain times selected from drain volume and drain flowrate profiles, similar to Figs. 3 and 4, calculated via the equation above. Here, instead of four exchanges of two liter fills each, the patient undergoes a first exchange using a two liter fill, and then four exchanges each of a 1.5 liter fill, totaling eight liters like above. PET characteristic is again high.
[0050] A modeled drain time and corresponding drain volume is shown for each cycle in Fig. 8B. In each case, the drain volume met the MDP requirement of 85% and the minimum drain flowrate met the FRT requirement of 75 ml/min shown in Fig. 8A. Fig. 8A also shows patient specific parameters of an FTP of 65% and a Qmax of 80 ml/min. As seen in fig. 8B, the drain time and drain volume vary from cycle to cycle because initial drain volume VDO varies from cycle to cycle. Here, the first drain volume is the biggest and the first drain time is the longest because the first fill is the biggest, namely, two liters versus 1.5 liters for the remaining four fills. The drain volumes and drain times increase from cycle two to cycle five because residual volume increases in each instance from cycle two to cycle five.
[0051] Figs. 8B and 9 highlight that five exchange or cycle therapy of Fig. 8B predicts a reduction of the maximum peak volume to roughly 2350 ml, which may be better suited for the particular patient. Fig. 8C shows the three-pore kinetic model's predicted UF removed for the therapy of Fig. 8B. The UF removed and overall clearances are comparable to those of Fig. 6C, and the patient absorbs less glucose, which is beneficial because the patient does not gain as much weight. Thus, assuming that the additional exchange can be done in a prescribed or desired total therapy duration, the therapy of Fig. 8B may be more desirable than the therapy of Fig. 6B. In any case, the more accurately predicted drain times and volumes discussed herein allow the therapies of Figs. 6B and 8B to be predicted more accurately, so that a better and more informed decision can be made for the patient.
[0052] It should be understood that various changes and modifications to the presently preferred embodiments described herein will be apparent to those skilled in the art. Such changes and modifications can be made without departing from the spirit and scope of the present subject matter and without diminishing its intended advantages. It is therefore intended that such changes and modifications be covered by the appended claims.

Claims

CLAIMSThe invention is claimed as follows:
1. A method of modeling a patient's peritoneal dialysis drain phase comprising: modeling a first segment of a drain phase curve as having a constant flowrate; modeling a second segment of a drain phase curve as having a decaying exponential flowrate; and incorporating a switching component into the first and second segments so that (i) at a first time the first segment is active and while the second segment is inactive and (ii) at a second time the first segment is inactive and while the second segment is active.
2. The method of Claim 1, which includes determining the constant flowrate empirically.
3. The method according to any one of the preceding claims, which includes determining the constant flowrate for a particular patient position during drain.
4. The method according to any one of the preceding claims, which includes determining a time of transition from the first segment to the second segment for the switching component empirically.
5. The method according to any one of the preceding claims, which includes a patient specific constant used with the decaying exponential flowrate empirically.
6. The method according to any one of the preceding claims, which includes using the modeled fist and second drain phase segments for at least one of: (i) determining a drain time for an automated peritoneal dialysis ("APD") machine; (ii) determining a dwell time for the APD machine; (iii) determining a drain time for a continuous ambulatory peritoneal dialysis therapy; (iv) setting a low flowrate alarm in an APD machine; (v) setting a minimum drain volume percentage in the APD machine; (vi) determining a dwell time for use in kinetically modeling a patient; and (vii) preventing overfilling of the patient.
7. The method of Claim 6, wherein the APD machine uses gravity for drain or pumps to drain.
8. The method according to any one of the preceding claims, which includes using the model to ensure that the drain flowrate does not fall below a certain level during therapy.
9. A model of a patient's peritoneal dialysis drain phase produced via the method of any one of the preceding claims.
10. A method of modeling a patient's peritoneal dialysis drain phase comprising: modeling a first segment of a drain phase curve as having a linear decrease in drain volume from the patient; modeling a second segment of a drain phase curve as having an exponentially decaying decrease in drain volume from the patient; and incorporating a switching component into the first and second segments so that (i) at a first time the first segment is active and while the second segment is inactive and (ii) at a second time the first segment is inactive and while the second segment is active.
11. The method of Claim 10, which includes choosing a time at which the patient's drain volume is calculated to drop to a certain level as a drain phase duration for therapy.
12. The method of Clam 11 , which includes ensuring that the certain level of drain volume removed over the drain phase duration is below a minimum drain volume level or percentage.
13. The method according to any one of Claims 10 to 12, which includes ensuring that the drain phase flowrate does not fall below a minimum level over the drain phase duration.
14. An apparatus for modeling a patient's peritoneal dialysis drain phase comprising: a computer readable medium modified to yield an instantaneous drain volume remaining in a patient, VD, which is equal to [VDO - Qmax*t]*Φ + [VDO *e~αt]*(l - Φ), wherein VDO is an initial patient drain volume; Qmax is a starting flowrate; Φ is a switching component; α is a decaying exponential constant; and t is time.
15. The apparatus of Claim 14, wherein VDO is estimated from a fill volume plus an expected amount of ultrafiltrate removed from the patient over a previous dwell phase.
16. The apparatus according to any one of Claims 14 or 15, wherein Qmax* is at least one of (i) patient specific, (ii) patient drain position specific, and (iii) determined empirically.
17. The apparatus according to any one of Claims 14 to 16, wherein Φ is either 1 or 0 depending on time t.
18. The apparatus of Claim 17, wherein Φ switches from 1 to 0 at a time t or a volume VD that is determined empirically.
19. The apparatus according to any one of Claims 14 to 18, wherein α is at least one of (i) patient specific and (iii) determined empirically.
20. The apparatus according to any one of Claims 14 to 19, wherein the computer readable medium is further modified to use VD to at least one of: (i) determine a drain time for an automated peritoneal dialysis ("APD") machine; (ii) determine a dwell time for the automated peritoneal dialysis ("APD") machine; (iii) determine a drain time for a continuous ambulatory peritoneal dialysis therapy; (iv) set a low flowrate alarm in an APD machine; (v) set a minimum drain volume percentage in the APD machine; (vi) determine a dwell time for use in kinetically modeling a patient; and (vii) prevent overfilling of the patient.
EP10705073A 2009-02-20 2010-02-19 Simulation of patient drain phase in peritoneal dialysis Active EP2398529B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/389,886 US8521482B2 (en) 2009-02-20 2009-02-20 Simulation of patient drain phase in peritoneal dialysis
PCT/US2010/024745 WO2010096659A1 (en) 2009-02-20 2010-02-19 Simulation of patient drain phase in peritoneal dialysis

Publications (2)

Publication Number Publication Date
EP2398529A1 true EP2398529A1 (en) 2011-12-28
EP2398529B1 EP2398529B1 (en) 2013-01-30

Family

ID=42115835

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10705073A Active EP2398529B1 (en) 2009-02-20 2010-02-19 Simulation of patient drain phase in peritoneal dialysis

Country Status (3)

Country Link
US (2) US8521482B2 (en)
EP (1) EP2398529B1 (en)
WO (1) WO2010096659A1 (en)

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9642960B2 (en) 2011-04-29 2017-05-09 Medtronic, Inc. Monitoring fluid volume for patients with renal disease
US9713665B2 (en) 2014-12-10 2017-07-25 Medtronic, Inc. Degassing system for dialysis
US9827361B2 (en) 2013-02-02 2017-11-28 Medtronic, Inc. pH buffer measurement system for hemodialysis systems
US9872949B2 (en) 2013-02-01 2018-01-23 Medtronic, Inc. Systems and methods for multifunctional volumetric fluid control
US9895479B2 (en) 2014-12-10 2018-02-20 Medtronic, Inc. Water management system for use in dialysis
US9943633B2 (en) 2009-09-30 2018-04-17 Medtronic Inc. System and method to regulate ultrafiltration
US10010663B2 (en) 2013-02-01 2018-07-03 Medtronic, Inc. Fluid circuit for delivery of renal replacement therapies
US10076283B2 (en) 2013-11-04 2018-09-18 Medtronic, Inc. Method and device to manage fluid volumes in the body
US10098993B2 (en) 2014-12-10 2018-10-16 Medtronic, Inc. Sensing and storage system for fluid balance
US10543052B2 (en) 2013-02-01 2020-01-28 Medtronic, Inc. Portable dialysis cabinet
US10695481B2 (en) 2011-08-02 2020-06-30 Medtronic, Inc. Hemodialysis system having a flow path with a controlled compliant volume
US10850016B2 (en) 2013-02-01 2020-12-01 Medtronic, Inc. Modular fluid therapy system having jumpered flow paths and systems and methods for cleaning and disinfection
US10857277B2 (en) 2011-08-16 2020-12-08 Medtronic, Inc. Modular hemodialysis system
US10874787B2 (en) 2014-12-10 2020-12-29 Medtronic, Inc. Degassing system for dialysis
US10905816B2 (en) 2012-12-10 2021-02-02 Medtronic, Inc. Sodium management system for hemodialysis
US10994064B2 (en) 2016-08-10 2021-05-04 Medtronic, Inc. Peritoneal dialysate flow path sensing
US11013843B2 (en) 2016-09-09 2021-05-25 Medtronic, Inc. Peritoneal dialysis fluid testing system
US11110215B2 (en) 2018-02-23 2021-09-07 Medtronic, Inc. Degasser and vent manifolds for dialysis
US11278654B2 (en) 2017-12-07 2022-03-22 Medtronic, Inc. Pneumatic manifold for a dialysis system
US11717600B2 (en) 2020-06-04 2023-08-08 Fresenius Medical Care Holdings, Inc. Administering dialysis treatment using a hybrid automated peritoneal dialysis system
US11806456B2 (en) 2018-12-10 2023-11-07 Mozarc Medical Us Llc Precision peritoneal dialysis therapy based on dialysis adequacy measurements
US11806457B2 (en) 2018-11-16 2023-11-07 Mozarc Medical Us Llc Peritoneal dialysis adequacy meaurements
US11883576B2 (en) 2016-08-10 2024-01-30 Mozarc Medical Us Llc Peritoneal dialysis intracycle osmotic agent adjustment
US11944733B2 (en) 2021-11-18 2024-04-02 Mozarc Medical Us Llc Sodium and bicarbonate control
US11965763B2 (en) 2021-11-12 2024-04-23 Mozarc Medical Us Llc Determining fluid flow across rotary pump
US12128165B2 (en) 2020-04-27 2024-10-29 Mozarc Medical Us Llc Dual stage degasser
US12154673B2 (en) 2021-08-02 2024-11-26 Mozarc Medical Us Llc Artificial intelligence assisted home therapy settings for dialysis

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8936720B2 (en) * 2010-09-17 2015-01-20 Baxter International Inc. Drain and fill logic for automated peritoneal dialysis
US9861733B2 (en) 2012-03-23 2018-01-09 Nxstage Medical Inc. Peritoneal dialysis systems, devices, and methods
EP3542840B1 (en) 2011-03-23 2023-04-26 NxStage Medical, Inc. Peritoneal dialysis systems
DE102011121668A1 (en) * 2011-12-20 2013-06-20 Fresenius Medical Care Deutschland Gmbh Method and device for preparing medical treatment devices
DE102014013229A1 (en) * 2014-09-05 2016-03-10 Fresenius Medical Care Deutschland Gmbh Apparatus for performing a tidal peritoneal dialysis treatment
DE102017110607A1 (en) * 2017-05-16 2018-11-22 Fresenius Medical Care Deutschland Gmbh peritoneal dialysis
US12048791B2 (en) 2017-06-24 2024-07-30 Nxstage Medical, Inc. Peritoneal dialysis fluid preparation and/or treatment devices methods and systems
US11033667B2 (en) 2018-02-02 2021-06-15 Medtronic, Inc. Sorbent manifold for a dialysis system
US11364328B2 (en) 2018-02-28 2022-06-21 Nxstage Medical, Inc. Fluid preparation and treatment devices methods and systems
US11850344B2 (en) 2021-08-11 2023-12-26 Mozarc Medical Us Llc Gas bubble sensor

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643201A (en) 1984-07-09 1997-07-01 Peabody; Alan M. Continuous peritoneal dialysis apparatus
SE9100471D0 (en) 1991-02-18 1991-02-18 Gambro Ab HOSE KIT PROVIDED FOR PERITONEAL DIALYSIS
ATE206061T1 (en) 1994-04-06 2001-10-15 Baxter Int DEVICE FOR OSCILLATING, TIDE-PULSED PERITONEAL DIALYSIS
US5670057A (en) * 1995-04-28 1997-09-23 Baxter International Inc. Apparatus and method for automatically performing peritoneal equilibration tests
AU5091198A (en) * 1996-10-22 1998-05-15 Hemocleanse, Inc. Continuous flow-through peritoneal dialysis (cfpd) method with control of intraperitoneal pressure
JP4180797B2 (en) 1998-04-02 2008-11-12 デビオテック ソシエテ アノニム Device for peritoneal dialysis and method of using this device
US6497676B1 (en) * 2000-02-10 2002-12-24 Baxter International Method and apparatus for monitoring and controlling peritoneal dialysis therapy
US6976973B1 (en) 2000-10-12 2005-12-20 Baxter International Inc. Peritoneal dialysis catheters
US6558334B2 (en) * 2000-10-19 2003-05-06 Florence Medical Ltd. Apparatus for diagnosing lesion severity, and method therefor
US7087036B2 (en) * 2002-05-24 2006-08-08 Baxter International Inc. Fail safe system for operating medical fluid valves
US7238164B2 (en) 2002-07-19 2007-07-03 Baxter International Inc. Systems, methods and apparatuses for pumping cassette-based therapies
AU2004279280B2 (en) 2003-10-13 2009-11-26 Fresenius Medical Care Deutschland Gmbh A device for carrying out a peritoneal dialysis treatment
JP4968074B2 (en) * 2005-10-18 2012-07-04 株式会社ジェイ・エム・エス Peritoneal function test apparatus and peritoneal function test program
US20080161751A1 (en) * 2006-12-29 2008-07-03 Plahey Kulwinder S Peritoneal dialysis therapy validation
US8057679B2 (en) 2008-07-09 2011-11-15 Baxter International Inc. Dialysis system having trending and alert generation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2010096659A1 *

Cited By (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9943633B2 (en) 2009-09-30 2018-04-17 Medtronic Inc. System and method to regulate ultrafiltration
US10293092B2 (en) 2011-04-29 2019-05-21 Medtronic, Inc. Electrolyte and pH monitoring for fluid removal processes
US10967112B2 (en) 2011-04-29 2021-04-06 Medtronic, Inc. Adaptive system for blood fluid removal
US9750862B2 (en) 2011-04-29 2017-09-05 Medtronic, Inc. Adaptive system for blood fluid removal
US10406268B2 (en) 2011-04-29 2019-09-10 Medtronic, Inc. Blood fluid removal system performance monitoring
US10064985B2 (en) 2011-04-29 2018-09-04 Medtronic, Inc. Precision blood fluid removal therapy based on patient monitoring
US11759557B2 (en) 2011-04-29 2023-09-19 Mozarc Medical Us Llc Adaptive system for blood fluid removal
US9700661B2 (en) 2011-04-29 2017-07-11 Medtronic, Inc. Chronic pH or electrolyte monitoring
US9968721B2 (en) 2011-04-29 2018-05-15 Medtronic, Inc. Monitoring fluid volume for patients with renal disease
US9642960B2 (en) 2011-04-29 2017-05-09 Medtronic, Inc. Monitoring fluid volume for patients with renal disease
US10179198B2 (en) 2011-04-29 2019-01-15 Medtronic, Inc. Electrolyte and pH monitoring for fluid removal processes
US10695481B2 (en) 2011-08-02 2020-06-30 Medtronic, Inc. Hemodialysis system having a flow path with a controlled compliant volume
US10722636B2 (en) 2011-08-02 2020-07-28 Medtronic, Inc. Hemodialysis system having a flow path with a controlled compliant volume
US10857277B2 (en) 2011-08-16 2020-12-08 Medtronic, Inc. Modular hemodialysis system
US10905816B2 (en) 2012-12-10 2021-02-02 Medtronic, Inc. Sodium management system for hemodialysis
US11786645B2 (en) 2013-02-01 2023-10-17 Mozarc Medical Us Llc Fluid circuit for delivery of renal replacement therapies
US10010663B2 (en) 2013-02-01 2018-07-03 Medtronic, Inc. Fluid circuit for delivery of renal replacement therapies
US9872949B2 (en) 2013-02-01 2018-01-23 Medtronic, Inc. Systems and methods for multifunctional volumetric fluid control
US10850016B2 (en) 2013-02-01 2020-12-01 Medtronic, Inc. Modular fluid therapy system having jumpered flow paths and systems and methods for cleaning and disinfection
US10532141B2 (en) 2013-02-01 2020-01-14 Medtronic, Inc. Systems and methods for multifunctional volumetric fluid control
US10543052B2 (en) 2013-02-01 2020-01-28 Medtronic, Inc. Portable dialysis cabinet
US10561776B2 (en) 2013-02-01 2020-02-18 Medtronic, Inc. Fluid circuit for delivery of renal replacement therapies
US9827361B2 (en) 2013-02-02 2017-11-28 Medtronic, Inc. pH buffer measurement system for hemodialysis systems
US10076283B2 (en) 2013-11-04 2018-09-18 Medtronic, Inc. Method and device to manage fluid volumes in the body
US11064894B2 (en) 2013-11-04 2021-07-20 Medtronic, Inc. Method and device to manage fluid volumes in the body
US9895479B2 (en) 2014-12-10 2018-02-20 Medtronic, Inc. Water management system for use in dialysis
US10874787B2 (en) 2014-12-10 2020-12-29 Medtronic, Inc. Degassing system for dialysis
US10195327B2 (en) 2014-12-10 2019-02-05 Medtronic, Inc. Sensing and storage system for fluid balance
US10098993B2 (en) 2014-12-10 2018-10-16 Medtronic, Inc. Sensing and storage system for fluid balance
US10420872B2 (en) 2014-12-10 2019-09-24 Medtronic, Inc. Degassing system for dialysis
US9713665B2 (en) 2014-12-10 2017-07-25 Medtronic, Inc. Degassing system for dialysis
US10994064B2 (en) 2016-08-10 2021-05-04 Medtronic, Inc. Peritoneal dialysate flow path sensing
US12194214B2 (en) 2016-08-10 2025-01-14 Mozarc Medical Us Llc Peritoneal dialysate flow path sensing
US11883576B2 (en) 2016-08-10 2024-01-30 Mozarc Medical Us Llc Peritoneal dialysis intracycle osmotic agent adjustment
US11013843B2 (en) 2016-09-09 2021-05-25 Medtronic, Inc. Peritoneal dialysis fluid testing system
US11679186B2 (en) 2016-09-09 2023-06-20 Mozarc Medical Us Llc Peritoneal dialysis fluid testing system
US11278654B2 (en) 2017-12-07 2022-03-22 Medtronic, Inc. Pneumatic manifold for a dialysis system
US11110215B2 (en) 2018-02-23 2021-09-07 Medtronic, Inc. Degasser and vent manifolds for dialysis
US11806457B2 (en) 2018-11-16 2023-11-07 Mozarc Medical Us Llc Peritoneal dialysis adequacy meaurements
US11806456B2 (en) 2018-12-10 2023-11-07 Mozarc Medical Us Llc Precision peritoneal dialysis therapy based on dialysis adequacy measurements
US12128165B2 (en) 2020-04-27 2024-10-29 Mozarc Medical Us Llc Dual stage degasser
US11717600B2 (en) 2020-06-04 2023-08-08 Fresenius Medical Care Holdings, Inc. Administering dialysis treatment using a hybrid automated peritoneal dialysis system
US12154673B2 (en) 2021-08-02 2024-11-26 Mozarc Medical Us Llc Artificial intelligence assisted home therapy settings for dialysis
US11965763B2 (en) 2021-11-12 2024-04-23 Mozarc Medical Us Llc Determining fluid flow across rotary pump
US11944733B2 (en) 2021-11-18 2024-04-02 Mozarc Medical Us Llc Sodium and bicarbonate control

Also Published As

Publication number Publication date
US20100217180A1 (en) 2010-08-26
EP2398529B1 (en) 2013-01-30
WO2010096659A1 (en) 2010-08-26
US8521482B2 (en) 2013-08-27
US20130317795A1 (en) 2013-11-28

Similar Documents

Publication Publication Date Title
US8521482B2 (en) Simulation of patient drain phase in peritoneal dialysis
US9348975B2 (en) Optimizing therapy outcomes for peritoneal dialysis
US10702645B2 (en) Drain and fill logic for automated peritoneal dialysis
EP2280746B1 (en) Smart patient transfer set for peritoneal dialysis
JP7627394B2 (en) Drain and fill logic for automated peritoneal dialysis.
US9433719B2 (en) Method for optimizing tidal therapies employing ultrafiltrate trending
EP3281657B1 (en) Peritoneal dialysis intracycle osmotic agent adjustment
Öberg et al. Optimizing automated peritoneal dialysis using an extended 3-pore model
US20110009810A1 (en) Peritoneal dialysis therapy with large dialysis solution volumes
US11951242B2 (en) Method for trending automated peritoneal dialysis treatments

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20110914

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 595587

Country of ref document: AT

Kind code of ref document: T

Effective date: 20130215

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602010004899

Country of ref document: DE

Effective date: 20130321

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 595587

Country of ref document: AT

Kind code of ref document: T

Effective date: 20130130

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

REG Reference to a national code

Ref country code: NL

Ref legal event code: VDEP

Effective date: 20130130

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130511

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130130

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130530

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130130

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130130

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130430

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130430

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130130

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130130

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130130

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130130

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130501

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130530

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130130

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130130

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130130

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130130

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130130

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130130

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130130

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130130

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130130

26N No opposition filed

Effective date: 20131031

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130219

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602010004899

Country of ref document: DE

Effective date: 20131031

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130130

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140228

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140228

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 6

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130130

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20150217

Year of fee payment: 6

Ref country code: SE

Payment date: 20150226

Year of fee payment: 6

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130130

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20100219

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130219

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130130

REG Reference to a national code

Ref country code: SE

Ref legal event code: EUG

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20161028

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160220

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160229

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20230109

Year of fee payment: 14

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20240219

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240219

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240219

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20250122

Year of fee payment: 16

OSZAR »